PET Imaging for Head and Neck Cancers.
| Autor: | Marcus C; Department of Nuclear Medicine and Molecular Imaging, Emory University Hospital, Atlanta, GA, USA. Electronic address: charlesmarcus1986@gmail.com., Sheikhbahaei S; Department of Radiology, Johns Hopkins Medical Institutions, 601 N. Caroline Street, JHOC 3235, Baltimore, MD 21287, USA., Shivamurthy VKN; Epilepsy Center, St. Francis Hospital and Medical Center, Trinity Health of New England, 114 Woodland Street, Hartford, CT 06105, USA., Avey G; Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Ave #3284, Madison, WI 53792, USA., Subramaniam RM; Dean's Office, Otago Medical School, University of Otago, 201 Great King Street, Dunedin 9016, New Zealand. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Radiologic clinics of North America [Radiol Clin North Am] 2021 Sep; Vol. 59 (5), pp. 773-788. |
| DOI: | 10.1016/j.rcl.2021.05.005 |
| Abstrakt: | Head and neck cancers are commonly encountered cancers in clinical practice in the United States. Fluorine-18-fluorodeoxyglucose ( 18 F-FDG) PET/CT has been clinically applied in staging, occult primary tumor detection, treatment planning, response assessment, follow-up, recurrent disease detection, and prognosis prediction in these patients. Alternative PET tracers remain investigational and can provide additional valuable information such as radioresistant tumor hypoxia. The recent introduction of 18 F-FDG PET/MR imaging has provided the advantage of combining the superior soft tissue resolution of MR imaging with the functional information provided by 18 F-FDG PET. This article is a concise review of recent advances in PET imaging in head and neck cancer. (Copyright © 2021 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|